BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• 

  Business

  Astellas Pays $50M for Access to Taysha’s Rett, GAN Programs

  Taysha Gene Therapies has entered into a strategic equity investment and licensing deal with Astellas. The latter stands to gain access to Taysha’s gene therapy development programs for Rett syndrome and GAN.

  October 25, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Novartis Axes NSCLC, Liver Transplant Programs in Q3 Report

  Novartis’ positive-third quarter growth report was slightly marred by several clinical setbacks that resulted in the termination of studies in liver transplant and non-small cell lung cancer.

  October 25, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Lieping Chen Founds Normunity to Take Pioneering PD-L1 Work to Next Level

  Normunity is launching its creation of novel precision anti-cancer immunotherapies, backed by $65 million of Series A financing, the company announced Tuesday.

  October 25, 2022

   · 

  2 min read

   · 

  Kaley Lefevre
• 

  Drug Development

  Early Data Indicate Gritstone’s Self-Amplifying mRNA Vaccine could Fill COVID-19 Gaps - Updated

  Data from two Phase I trials indicate Gritstone Bio’s samRNA vaccine can safely induce a strong and durable immune response against COVID-19.

  October 25, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Rare Liver Disease Wins Mount as Mirum’s PFIC Trial Meets Endpoint - Updated

  Mirum Pharmaceuticals announced that Livmarli oral solution met its primary endpoint in the Phase III MARCH study in young patients with progressive familial intrahepatic cholestasis.

  October 25, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  On the Horizon, Needle-Free Vaccines could Offer Better Protection and Access

  In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery, edible and intranasal vaccines.

  October 25, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Drug Development

  AstraZeneca Sees Mixed Results in Phase III EoE Trial

  AstraZeneca reported Tuesday that its Phase III MESSINA trial hit one primary endpoint but missed the other. The study was evaluating Fasenra in eosinophilic esophagitis.

  October 25, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  GSK Abandons Cell Therapy Collaboration with Lyell

  GSK terminated its cell therapy pact with Lyell Immunopharma. It’s opting to advance its own programs without use of Lyell’s T-cell modulating technologies that were at the center of the partnership.

  October 25, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Ipsen’s FOP Saga Continues as FDA Postpones Oct. 31 Adcom

  Ipsen hit another stumbling block in its bid for an FOP approval as the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee postponed its meeting on the NDA for palovarotene capsules.

  October 25, 2022

   · 

  2 min read

   · 

  Rosemary Scott
• 

  Business

  BioSpace NextGen Bio 2022 Winners: Where are They Now?

  BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they’ve done to earn their place on the list - and what’s on the horizon.

  October 25, 2022

   · 

  7 min read

   · 

  Heather McKenzie